EAM Investors’s Annovis Bio ANVS Stock Holding History

EAM Investors’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-48,643	Closed	-$4.16M	–	285
2021 Q2	$4.16M	Buy	48,643 +4,003	+9%	+$185K	0.64%	15
2021 Q1	$1.25M	Buy	+44,640	New	+$955K	0.19%	263

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

WFAG

Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.29B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

EAM Investors's ANVS Position: Q3 2021 in Review

EAM Investors sold out of Annovis Bio (ANVS) in Q3 2021, closing a stake of 48,643 shares — an estimated $4.16M sold.

EAM Investors first reported a position in ANVS in Q1 2021 and held it in 2 quarters. The position peaked at $4.16M in Q2 2021. 38 funds tracked by Wall St. Rank hold ANVS as of Q3 2021.

EAM Investors reported no remaining Annovis Bio position as of Q3 2021 after selling out during the quarter.
EAM Investors sold 48,643 Annovis Bio shares in Q3 2021, an estimated $4.16M.
EAM Investors first reported a position in Annovis Bio in Q1 2021 and held it in 2 quarters.
EAM Investors's Annovis Bio position peaked at $4.16M in Q2 2021.
38 funds tracked by Wall St. Rank held Annovis Bio as of Q3 2021.

Based on EAM Investors's 13F filing for Q3 2021, filed 12 Nov 2021.